ArticleFuture oncology (London, England)2022

First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.

Alycia Hatashima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.